The CYD tetravalent dengue vaccine candidate is being evaluated for protective efficacy
against symptomatic dengue in Phase 3 efficacy trials. The laboratory test algorithm to …

Background Dengue diagnosis confirmation and surveillance are widely based on
serological assays to detect anti-dengue IgM or IgG antibodies since such tests are …

Background In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine,
estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) …

Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue
vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we …

Background We previously reported that vaccination with the tetravalent dengue vaccine
(CYD-TDV; Dengvaxia) may bias the diagnosis of dengue based on immunoglobulin M …

There are 4 serologically distinct dengue viruses (DENVs), which contemporarily cocirculate
in a majority of countries of the tropical and subtropical belt in Latin America, Asia-Pacific …

CYD-TDV is a live, attenuated, tetravalent dengue vaccine licensed in 21 countries. We
undertook a post-hoc analysis of the long-term efficacy of CYD-TDV during the surveillance …

Background CYD-TDV, a live, attenuated, tetravalent dengue vaccine, has been approved
for the prevention of symptomatic dengue in previously dengue exposed individuals. This …

The CYD-TDV vaccine is licensed in multiple endemic countries based on vaccine efficacy
(VE) against symptomatic, virologically confirmed dengue demonstrated in two phase 3 trials …

Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine
(CYD-TDV) that is in late-stage development. The present review summarizes the different …